Nipah virus: epidemiology, pathology, immunobiology and advances in diagnosis, vaccine designing and control strategies – a comprehensive review

• Main Authors: Raj Kumar Singh, Kuldeep Dhama, Sandip Chakraborty, Ruchi Tiwari, Senthilkumar Natesan, Rekha Khandia, Ashok Munjal, Kranti Suresh Vora, Shyma K. Latheef, Kumaragurubaran Karthik, Yashpal Singh Malik, Rajendra Singh, Wanpen Chaicumpa, Devendra T. Mourya
• Format: Article
• Language: English
• Published: Taylor & Francis Group 2019-01-01
• Series: Veterinary Quarterly
• Subjects: nipah virus (niv); bats; diagnosis; encephalitis; epidemiology; pathology; prevention; control; vaccines; therapeutics; zoonosis
• Online Access: http://dx.doi.org/10.1080/01652176.2019.1580827
• ISSN: 0165-2176; 1875-5941

Nipah (Nee-pa) viral disease is a zoonotic infection caused by Nipah virus (NiV), a paramyxovirus belonging to the genus Henipavirus of the family Paramyxoviridae. It is a biosafety level-4 pathogen, which is transmitted by specific types of fruit bats, mainly Pteropus spp. which are natural reservoir host. The disease was reported for the first time from the Kampung Sungai Nipah village of Malaysia in 1998. Human-to-human transmission also occurs. Outbreaks have been reported also from other countries in South and Southeast Asia. Phylogenetic analysis affirmed the circulation of two major clades of NiV as based on currently available complete N and G gene sequences. NiV isolates from Malaysia and Cambodia clustered together in NiV-MY clade, whereas isolates from Bangladesh and India clusterered within NiV-BD clade. NiV isolates from Thailand harboured mixed population of sequences. In humans, the virus is responsible for causing rapidly progressing severe illness which might be characterized by severe respiratory illness and/or deadly encephalitis. In pigs below six months of age, respiratory illness along with nervous symptoms may develop. Different types of enzyme-linked immunosorbent assays along with molecular methods based on polymerase chain reaction have been developed for diagnostic purposes. Due to the expensive nature of the antibody drugs, identification of broad-spectrum antivirals is essential along with focusing on small interfering RNAs (siRNAs). High pathogenicity of NiV in humans, and lack of vaccines or therapeutics to counter this disease have attracted attention of researchers worldwide for developing effective NiV vaccine and treatment regimens.